Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IN-2402
- Development stage
- Preclinical
- Lead developer
- Indivumed
- Modality
- Small Molecules
01
Overview
IN-2402 is a preclinical small molecule therapeutic being developed by Indivumed for the treatment of colorectal cancer (CRC). The drug was identified through Indivumed's proprietary target identification platform, which utilizes multi-omics datasets derived from patient samples to discover novel oncology targets. As of September 2025, IN-2402 is in the 'Hit to Lead' stage of development. While the specific molecular target has not been publicly disclosed, the program is part of a broader pipeline focused on addressing unmet needs in CRC and other solid tumors through precision medicine approaches.
Beyond the preview
Go deeper on IN-2402.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IN-2402.